vTv Therapeutics (NASDAQ:VTVT – Get Free Report) was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a report released on Wednesday,Zacks.com reports.
VTVT has been the subject of a number of other reports. Wall Street Zen raised shares of vTv Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, March 14th. Weiss Ratings restated a “sell (d-)” rating on shares of vTv Therapeutics in a research note on Friday, March 27th. Evercore assumed coverage on shares of vTv Therapeutics in a report on Thursday, March 12th. They set an “outperform” rating and a $44.00 target price for the company. BTIG Research reiterated a “buy” rating and issued a $49.00 price target on shares of vTv Therapeutics in a research note on Wednesday, March 11th. Finally, Roth Mkm assumed coverage on shares of vTv Therapeutics in a report on Thursday, January 22nd. They issued a “buy” rating and a $58.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $53.00.
Get Our Latest Report on vTv Therapeutics
vTv Therapeutics Stock Up 21.3%
vTv Therapeutics (NASDAQ:VTVT – Get Free Report) last posted its earnings results on Wednesday, May 13th. The biotechnology company reported $1.65 earnings per share for the quarter, topping analysts’ consensus estimates of $0.21 by $1.44. The business had revenue of $36.84 million for the quarter, compared to analyst estimates of $20.00 million. As a group, analysts expect that vTv Therapeutics will post -2.66 earnings per share for the current year.
Institutional Investors Weigh In On vTv Therapeutics
A number of institutional investors have recently modified their holdings of VTVT. Baker BROS. Advisors LP grew its stake in shares of vTv Therapeutics by 52.4% in the third quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock valued at $3,463,000 after acquiring an additional 51,000 shares in the last quarter. Geode Capital Management LLC raised its stake in vTv Therapeutics by 84.3% in the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock worth $1,128,000 after purchasing an additional 12,896 shares in the last quarter. Goldman Sachs Group Inc. acquired a new stake in vTv Therapeutics in the 4th quarter worth about $221,000. Finally, 683 Capital Management LLC bought a new stake in vTv Therapeutics in the 4th quarter valued at about $731,000. Institutional investors own 17.51% of the company’s stock.
About vTv Therapeutics
vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.
The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.
Featured Stories
- Five stocks we like better than vTv Therapeutics
- Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs
- 2 Ways to Play the Big Pharma Patent Cliff
- YETI Rallies After Earnings Beat and Raised Outlook
- How the 3 Leading Quantum Firms Stack Up After Q1 Earnings
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
